v3.26.1
Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting [Line Items]          
Revenues $ 29,105 $ 29,734 $ 53,535 $ 60,305  
Operating expenses:          
Cost of revenues 2,209 1,151 3,436 2,045  
Selling and marketing 13,754 15,195 27,890 26,035  
Research and development   8,351   16,442  
General and administrative 7,862 7,275 18,032 15,476  
Transaction costs 502   6,886    
Total segment operating expenses 43,463 31,972 86,861 59,998  
(Loss) income from operations (14,358) (2,238) (33,326) 307  
Other segment (loss) income, net:          
Interest income 740 941 1,483 1,797  
Other (expense) income, net (943) (488) (830) (301)  
Change in fair value of warrant liability 132 212 220 2,467  
Benefit (provision) for income taxes 164 (662) (385) (1,563)  
Net segment (loss) income (14,265) (2,235) (32,838) 2,707  
Reconciliation of profit or loss          
Other general and administrative expenses 5 2 11 5  
Net (loss) income (14,270) (2,237) (32,849) 2,702  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 1,833 1,120 4,658 1,943  
Total assets 199,255   199,255   $ 219,763
Purchase of property and equipment     440 457  
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 122 47 300 47  
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 971 982 2,518 1,724  
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 79 62 194 143  
Location, Statement of Income, Balance [Axis]: us-gaap:SellingAndMarketingExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 661 29 1,646 29  
Related Parties          
Operating expenses:          
Research and development 4,836   4,836    
Non-Related Party          
Operating expenses:          
Research and development 14,300 8,351 25,781 16,442  
Gyre Pharmaceuticals          
Segment Reporting [Line Items]          
Revenues 29,097 26,771 51,616 48,829  
Operating expenses:          
Cost of revenues 2,209 1,151 3,436 2,045  
Selling and marketing 13,754 15,195 27,890 26,035  
Research and development   3,337   6,366  
General and administrative 4,268 2,858 9,025 6,414  
Transaction costs 0   0    
Total segment operating expenses 34,764 22,541 60,350 40,860  
(Loss) income from operations (5,667) 4,230 (8,734) 7,969  
Other segment (loss) income, net:          
Interest income 252 271 517 555  
Other (expense) income, net (391) (507) (818) (729)  
Change in fair value of warrant liability 0 0 0 0  
Benefit (provision) for income taxes 165 (662) (456) (1,563)  
Net segment (loss) income (5,641) 3,332 (9,491) 6,232  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 1,206 349 2,919 427  
Total assets 139,241   139,241   138,407
Purchase of property and equipment     386 378  
Gyre Pharmaceuticals | Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 122 47 300 47  
Gyre Pharmaceuticals | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 344 273 779 351  
Gyre Pharmaceuticals | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 79 0 194 0  
Gyre Pharmaceuticals | Location, Statement of Income, Balance [Axis]: us-gaap:SellingAndMarketingExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 661 29 1,646 29  
Gyre Pharmaceuticals | Related Parties          
Operating expenses:          
Research and development 4,836   4,836    
Gyre Pharmaceuticals | Non-Related Party          
Operating expenses:          
Research and development 9,697   15,163    
Gyre          
Segment Reporting [Line Items]          
Revenues 8 2,963 1,919 11,476  
Operating expenses:          
Cost of revenues 0 0 0 0  
Selling and marketing 0 0 0 0  
Research and development   5,014   10,076  
General and administrative 3,594 4,417 9,007 9,062  
Transaction costs 502   6,886    
Total segment operating expenses 8,699 9,431 26,511 19,138  
(Loss) income from operations (8,691) (6,468) (24,592) (7,662)  
Other segment (loss) income, net:          
Interest income 488 670 966 1,242  
Other (expense) income, net (552) 19 (12) 428  
Change in fair value of warrant liability 132 212 220 2,467  
Benefit (provision) for income taxes (1) 0 71 0  
Net segment (loss) income (8,624) (5,567) (23,347) (3,525)  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 627 771 1,739 1,516  
Total assets 59,657   59,657   81,000
Purchase of property and equipment     54 79  
Gyre | Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 0 0 0 0  
Gyre | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 627 709 1,739 1,373  
Gyre | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 0 62 0 143  
Gyre | Location, Statement of Income, Balance [Axis]: us-gaap:SellingAndMarketingExpense          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 0 $ 0 0 0  
Gyre | Related Parties          
Operating expenses:          
Research and development 0   0    
Gyre | Non-Related Party          
Operating expenses:          
Research and development 4,603   10,618    
Other Unallocated Amount          
Supplemental disclosure of stock-based compensation expense:          
Total assets $ 357   357   $ 356
Purchase of property and equipment     $ 0 $ 0